Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

February 20, 2027

Study Completion Date

July 20, 2027

Conditions

Advanced Renal Cell Carcinoma (aRCC)

Interventions

DRUG

Envafolimab Injection, Axitinib Tablets

"Envafolimab + Axitinib~* Envafolimab 400 mg, subcutaneous injection, day 1, every 3 weeks;~* Axitinib 5 mg, orally, twice daily"

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER